Caring Cross cooperates with Companies that are like-minded in their social responsibility and yet create tremendous value for their stakeholders. We collaborate on a range of activities that adds value to the gene therapy industrial ecosystem.
Below are examples of some of the partnerships we have with companies.
Vector BioMed: Revolutionizing Viral Vector Manufacturing
Vector BioMed, Inc. founded as a for-profit Benefit or B Corporation, and has rapidly become a leading viral vector manufacturing CDMO.
Why Vector BioMed is becoming the go-to choice for Lentiviral vector manufacturing services for the industry:
Lentiviral Vector Technology: Vector BioMed was established on novel and highly efficient Lentiviral vector manufacturing technology developed at Caring Cross. Vectors are a critical material in the manufacture of CAR-T cell and Stem Cell gene therapies.
Custom Lentiviral Vectors: Vector BioMed manufactures custom Lentiviral vectors for investigators containing their desired specific sequence which is optimized using our experience and algorithms.
Generic off-the-shelf CAR vectors: Vector BioMed manufactures GMP off-the-shelf CAR vectors where patents have expired and there is freedom to operate. Companies wanting to establish CAR-T cell manufacturing capabilities in their countries find exceptional quality and value with Vector BioMed’s off-the-shelf CAR offerings.
Targeted Lentiviral vectors: Vector BioMed produces targeted Lentiviral vectors that are specific for T cells that can be used for in vivo gene therapy.
Economical CAR-T cell manufacturing process: Vector BioMed offers the simple and robust CAR-T cell manufacturing process to companies wanting to establish their own CAR-T cell program.
Experience Matters: Senior members of the Vector BioMed team have decades of experience manufacturing Lentiviral vectors, which is second to none in the industry.
GMP Facilities: Vector BioMed occupies world-class GMP manufacturing facilities in Gaithersburg, Maryland, USA.
Affordability: Vector BioMed manufactures GMP Lentiviral vectors for the gene therapy industry at about half the price of competitors.
For more information of Vector BioMed’s products and services, visit www.vectorbiomed.com.
Germfree partnership with Caring Cross to enable point-of-care GMP manufacturing
Caring Cross and Germfree announced a partnership to revolutionize the accessibility of cellular gene therapies (CGTs). By combining Germfree’s advanced mobile cleanroom technology with Caring Cross’s innovative manufacturing expertise and pipeline of CGT products, the partners aim to enable a decentralized, point-of-care manufacturing model at hospital centers where patients come for care.
This partnership addresses the current limitations of CGTs, which are often expensive, time-consuming to produce, and only available in affluent regions. By localizing manufacturing, the partnership seeks to make CGTs more accessible to patients worldwide, especially those with intractable diseases like late-stage blood cancers and sickle cell disease.
Building on a three-year collaboration, including a pilot project with Brazil’s Fundação Oswaldo Cruz (Fiocruz), Germfree and Caring Cross will work together to develop a comprehensive, end-to-end solution for on-site manufacturing of CAR-T and other CGTs. Germfree will provide advanced hardware and digital platforms to ensure robust quality control, while Caring Cross will develop therapeutic products, establish manufacturing protocols, and train healthcare professionals.
Press Release
Germfree and Caring Cross Partner to Transform Access to Cellular Gene Therapies
Cytiva supports Caring Cross to develop CAR-T cell therapy in low-to-middle-income countries
Caring Cross and Cytiva are collaborating to contribute their respective expertise to develop a CAR-T cell therapy. Cytiva will provide its technologies and solutions in support of Caring Cross’ mission to use manufacturing and distribution models to enable the affordability and accessibility of CAR-T cell therapies to diverse patient populations and treatment indications.
Cytiva will be providing equipment and software packages including the Sepax C-Pro, a compact, versatile place of care instrument with capabilities to automatically isolate, concentrate, wash and dilute cellular products and subsequently reduce total processing times of CAR-T manufacturing. Other equipment provided includes the VIA Thaw and VIA Freeze instruments designed to streamline freezing and thawing processes resulting in increased efficiency, while minimizing contamination risks of traditional methods such as water baths.
Press Release
ImmunoAct partnership to commercialize of Caring Cross TriCAR in India
Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT), a leading Indian research and cell and gene therapy company, have announced a partnership to develop and commercialize a multi-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy for leukemia and lymphoma.
The TriCAR-T immunotherapy is designed to address the issue of relapse that can occur in patients with leukemia or lymphoma treated with single-target anti-CD19 CAR-T cell therapies. Under the terms of the agreement, Caring Cross will provide a TriCAR-T cell immunotherapy for clinical development, manufacturing, and commercialization at ImmunoACT’s facilities in India.
Press Release
If you are interested in partnering with Caring Cross please send an email to [email protected].
